Paper Details

  1. Home
  2. Paper Details

Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis.

Author: AndersenJohanna Balslev, MagyariMelinda, SellebjergFinn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the association of fetal exposure to disease-modifying drugs (DMDs) used to treat multiple sclerosis with adverse pregnancy outcomes. The study found no increased association of adverse pregnancy outcomes in newborns with fetal exposure to DMDs compared to DMD-unexposed pregnancies or the general population.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND PURPOSE: Data on pregnancy outcomes following fetal exposure to disease-modifying drugs (DMDs) in women with multiple sclerosis (MS) are sparse although growing. METHODS: Data from the Danish Multiple Sclerosis Registry were linked with nationwide registries enabling an investigation...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092676/

データ提供：米国国立医学図書館（NLM）

A Journey Through the Desert of Pregnancy and Multiple Sclerosis

Navigating pregnancy while living with multiple sclerosis (MS) can be a challenging journey, filled with uncertainties about the safety of medications. This research delves into the impact of various disease-modifying drugs (DMDs) on pregnancy outcomes. The authors found no increased association of adverse pregnancy outcomes in newborns exposed to DMDs compared to either DMD-unexposed pregnancies or the general population.

Reassuring Findings for Women with MS

The study provides reassuring data for women with MS who are considering pregnancy. The lack of association between DMD exposure and adverse pregnancy outcomes suggests that these medications may not pose an increased risk to the developing fetus.

A Guiding Light for Women with MS and Their Families

This study offers valuable information for women with MS and their families, helping them make informed decisions about pregnancy and medication use. It highlights the importance of ongoing research and collaboration between healthcare providers and patients to ensure optimal outcomes during pregnancy.

Dr. Camel's Conclusion

This research is like a cool oasis in the desert, offering relief and reassurance for women with MS who are navigating the journey of pregnancy. It underscores the importance of evidence-based medicine and the power of research to illuminate pathways towards better healthcare for all.

Date :
  1. Date Completed 2022-12-16
  2. Date Revised 2023-04-15
Further Info :

Pubmed ID

36098960

DOI: Digital Object Identifier

PMC10092676

Related Literature

Article Analysis
・Effects of natalizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.